LY3009104

LY3009104 (Baricitinib, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19.


Cat. No.: EX-A413	Purity: 99%+

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
1g	825	In-stock
5g	2475	In-stock
10g	3960	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Baricitinib
Synonyms 2	INCB028050
CAS No.	1187594-09-7
Purity	99%+
Formula	C16H17N7O2S
Mol Weight	371.417
Appearance	Solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1] Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol, 2010, 184(9), 5298-5307. [2] Kontzias A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol, 2012, 12(4), 464-470. [3] Norman P, et al. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat, 2012, 22(10), 1233-1249. [4] Norman P, et al. Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition. Expert Opin Ther Pat, 2012, 22(9), 1105-1109.
CoA	CoA of LY3009104

Smiles:	CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1


		Search